Practice advisory on the appropriate use of NSAIDs in primary care

Cyclo-oxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are important in managing acute and chronic pain secondary to inflammation. As a greater understanding of the risks of gastrointestinal (GI), cardiovascular (CV) and renal events with NSAIDs use has emerged, guidelines have evolved to reflect differences in risks among NSAIDs. Updated guidelines have yet to reflect new evidence from recent trials which showed similar CV event rates with celecoxib compared to naproxen and ibuprofen, and significantly better GI tolerability for celecoxib. This practice advisory paper aims to present consensus statements and associated guidance regarding appropriate NSAID use based on a review of current evidence by a multidisciplinary group of expert clinicians. This paper is especially intended to guide primary care practitioners within Asia in the appropriate use of NSAIDs in primary care. Following a literature review, group members used a modified Delphi consensus process to determine agreement with selected recommendations. Agreement with a statement by 75% of total voting members was defined a priori as consensus. For low GI risk patients, any nonselective NSAID plus proton pump inhibitor (PPI) or celecoxib alone is acceptable treatment when CV risk is low; for high CV risk patients, low-dose celecoxib or naproxen plus PPI is appropriate. For high GI risk patients, celecoxib plus PPI is acceptable for low CV risk patients; low-dose celecoxib plus PPI is appropriate for high CV risk patients, with the alternative to avoid NSAIDs and consider opioids instead. Appropriate NSAID prescription assumes that the patient has normal renal function at commencement, with ongoing monitoring recommended. In conclusion, appropriate NSAID use requires consideration of all risks

Antineutrophil cytoplasmic antibody vasculitis associated with mycobacterium avium intracellulare infection

ABSTRACT. A variety of possible associations between infection and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis have been reported. We describe a 75-year-old woman who presented with chronic nonproductive cough, migratory polyarthralgias, and microscopic hematuria. She had an elevated perinuclear ANCA and antimyeloperoxidase antibody. She had a positive PPD test and a cavitary lesion in the right upper lung lobe; biopsy of the lung lesion showed granulomatous vasculitis, but the culture grew Mycobacterium avium intracellulare (MAI According to the Chapel Hill international consensus definitions, which use the vessel size as the determinant for classification of vasculitides, Wegener's granulomatosis (WG), microscopic polyangiitis, and Churg-Strauss syndrome are described as small-vessel vasculitides and are commonly associated with antineutrophil cytoplasmic antibodies (ANCA). They are acknowledged as ANCA associated vasculitis syndromes 1 . The association of infections and ANCA vasculitis has been noted by various authors, especially in WG 2 . Recently we encountered a patient with ANCA associated vasculitis and pulmonary Mycobacterium avium intracellulare (MAI) infection, suggesting a possible association between ANCA associated vasculitis and MAI infections. We emphasize the clinical similarities between ANCA associated vasculitis and MAI infection, since treatment of vasculitis with immunosuppressive agents could be devastating in patients with MAI infection. CASE REPORT A 75-year-old woman was referred by her primary physician for evaluation of chronic nonproductive cough, migratory polyarthralgias, and microscopic hematuria. She had these symptoms intermittently for 5 years, but they had worsened in the past 2-3 months. Her history included hypertension and chronic kidney disease with a baseline serum creatinine of 1.4 mg/dl. Pertinent data included an elevated erythrocyte sedimentation rate (ESR; 110 mm/h), perinuclear ANCA (pANCA) 1:640 (normal < 1:20), and antimyeloperoxidase antibody (MPO) 29 (normal < 6). She also had a positive PPD test (20 mm erythema and induration) and a cavitary lesion in the right upper lung field. She underwent a right thoracoscopic wedge resection. The histology revealed granulomatous vasculitis with focally abundant eosinophils Two months after discontinuation of MAI treatment, she had episodes of hemoptysis, dyspnea, migratory polyarthritis, and new purpuric skin lesions at the second, third and fourth finger pulps and the left calf. She had worsening renal function (creatinine 2.1 mg/dl). A radiograph showed chronic fibrotic changes in both lower lung fields. A computer tomographic scan of the chest showed diffuse airspace disease in the right lower lung field with bronchiectatic change in the right upper lung field. pANCA and MPO were elevated (1:320 and 29, respectively). Cytoplasmic ANCA (cANCA) and antiproteinase 3 antibody were negative. A urinalysis revealed 1+ proteinuria and 194 red blood cells per high power field; no cast was noted. A skin biopsy from the left calf showed necrotizing vasculitis of medium and small arteries with occasional eosinophil

Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs

PURPOSE: A summary of the basic science underlying the current controversies regarding cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drugs (NSAIDs), including data on their cardiovascular safety, their gastrointestinal (GI) benefits, cost-effectiveness, physician-prescribing trends, and recommendations for prescribing these agents is presented. SUMMARY: A number of randomized controlled trials (RCTs) have reported that COX-2-selective NSAIDs increase cardiovascular events, although there appear to be gradations of risks among the COX-2-selective NSAIDs. In addition, traditional NSAIDs may increase the risk for cardiovascular events, complicating the interpretation of RCTs that use traditional NSAIDs as comparators. Selective inhibitors of COX-2-selective NSAIDs are effective antiinflammatory and analgesic drugs with improved upper-GI safety compared to traditional NSAIDs. Data on the cost-effectiveness of COX-2-selective NSAIDs indicate that they should be limited to patients at high risk for upper-GI adverse effects. However, they had been increasingly used in patients with lower GI risks until recent events reversed that trend. Circumstances under which COX-2-selective NSAIDs may be appropriate are in patients at high GI risk and in patients who did not respond to multiple traditional NSAIDs. The national spotlight in the United States on NSAID-related adverse events and recent lawsuits against health care providers prescribing COX-2-selective NSAIDs further highlights the need for provider-patient communication and risk disclosure. The relative cardiovascular risks of NSAIDs are similar in magnitude to other currently prescribed therapies. CONCLUSION: Health care providers must consider the efficacy, GI and cardiovascular risks, concomitant medications, and costs when determining the appropriateness of COX-2-selective NSAID therapy

The efficacy of intra-articular triamcinolone acetonide 10 mg vs. 40 mg in patients with knee osteoarthritis: a non-inferiority, randomized, controlled, double-blind, multicenter study

Abstract Background Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage volume as compared to saline IA. Objective To determine the non-inferiority of 10-mg versus 40-mg of triamcinolone acetonide (TA) for treatment of pain in symptomatic knee osteoarthritis at week 12. Methods This was a double-blind, randomized, controlled trial conducted in 84 symptomatic knee osteoarthritis patients. The 10-mg or 40-mg of TA were 1:1 randomized and injected to the affected knees. The primary outcome was the 12-week difference from baseline in pain VAS, with a pre-specified lower margin for non-inferiority of 10 mm. The measuring instruments used were: Visual analog scale (VAS: 0–10), modified Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), EuroQol Group 5 Dimensions (EQ5D), Knee Injuries and Osteoarthritis Outcome Score (KOOS) questionnaire, chair standing test and 20-m walking time at baseline, at week 4, and week 12 after randomization. Adverse events were recorded. Results Baseline characteristics were similar between two groups. The mean differences of pain VAS (95% confidence interval: CI) between the two groups at baseline and week 12 were 0.8 (-0.8, 2.4) with p of 0.002 for non-inferiority. There were no differences in pain reduction and quality of life improvement between 10-mg and 40-mg groups. The mean differences (95%CI) of WOMAC, KOOS pain, EQ5D and KOOS quality of life between baseline and week 12 were 0.4 (-1.1, 1.9). -8.7 (-21.3, 3.9), 1.3(-7.1, 9.6) and 1.8 (-11.5, 15.0), respectively. There were significant improvements in pain and quality of life between baseline and week 12 in both groups. Conclusion The 10 mg of TA is non-inferior to 40 mg TA in improving pain in patients with symptomatic knee OA. Both 10 mg and 40 mg of TA significantly improved pain and quality of life in patients with symptomatic knee OA. Trial registration TCTR, I TCTR20210224002. Retrospectively registered 24 February 2021, http://www.thaiclinicaltrials.org/show/TCTR2021022400

Prevalence of low trabecular bone score and its association with disease severity and activity in patients with axial spondyloarthritis

Abstract Axial spondyloarthritis (axSpA) increases the risk of osteoporosis and vertebral fractures. Bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) has limitations in axSpA patients. Trabecular bone score (TBS) indirectly assesses bone microarchitecture and can be used to predict fracture risk. However, few studies have investigated the role of TBS in axSpA patients. The objective of this study were to compare TBS between axSpA patients and 1:1 sex- and age-matched healthy volunteers and determine factors associated with low TBS in axSpA patients. A cross-sectional study was conducted in two tertiary-care hospitals. A total of 137 axSpA patients and healthy volunteers were enrolled. Demographics, disease characteristics, and risk factors for osteoporosis were recorded. TBS, BMD at the lumbar spine, hip, and vertebral fractures were assessed by DXA. Low TBS was defined as a TBS value < 1.230. Factors associated with low TBS were examined by logistic regression. Most patients were male (75.9%) and tested positive for HLA-B27 (88.3%). The mean (SD) age was 42.8 (12.0) years. The mean (SD) of TBS in the axSpA patients was lower than those in the healthy volunteers [1.402 (0.107) vs 1.440 (0.086), respectively; p = 0.002]. The mean (SD) of lumbar BMD in the axSpA patients was higher than in healthy volunteers [1.186 (0.212) vs 1.087 (0.124), p < 0.001], whereas the mean (SD) of femoral neck BMD in the axSpA group was lower than that in the healthy volunteers [0.867 (0.136) vs 0.904 (0.155), p = 0.038]. Disease severity as indicated by sacroiliac joint fusion and a high ASDAS score were associated with low TBS with the odds ratios (95% confidence interval) of 11.8 (1.2–115.4) and 5.2 (1.6–16.9), respectively. In conclusion, axSpA patients had a higher prevalence of low TBS than healthy volunteers. Sacroiliac joint fusion and a high ASDAS score were associated with low TBS